RESEARCH TRIANGLE PARK — BioCryst Pharmaceuticals has appointed Anthony Doyle as senior vice president and chief financial officer (CFO).
Doyle joins the RTP-based BioCryst from Worldwide Clinical Trials, a full-service global contract research organization, where he has served as CFO since 2014.
From 2004-2012, he held a series of increasingly responsible roles at General Electric (GE), moving through financial planning and analysis, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs.
BioCryst chief financial officer Anthony Doyle. Source: LinkedIn
He then led risk and pricing for GE Healthcare’s $1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company.
“Anthony is a seasoned, global, life science leader who brings a track record of accomplishment helping build and grow businesses. This is exactly what we need as we prepare for our first launch with berotralstat and advance our very exciting pipeline,” said Jon Stonehouse, chief executive officer of BioCrys, in a statement.
BioCryst discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs, including berotralstat (BCX7353), an oral treatment for hereditary angioedema; and BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
BioCryst reports more revenue, smaller loss than Street expectations
